Of the 52 new drugs approved in the past decade, 21% were categorized as first in class, but more innovations are needed for skin diseases with unmet therapeutic needs, the authors said.
This research letter highlights opportunities for researchers to develop more innovative treatments for skin disease, especially for conditions that have unmet therapeutic needs.